Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

Overview of attention for article published in Arthritis Research & Therapy, April 2010

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 5 patents

Citations

dimensions_citation: 68 Dimensions

Readers on

mendeley: 67 Mendeley

Summary Patents Dimensions citations

So far, Dimensions has found 68 publications that cite this research output.

68

The most recent citing publications are shown below. View all 68 publications that cite this research output on Dimensions.

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus Erythematosus

Preprint in medRxiv (April 2024)

SLE serum induces altered goblet cell differentiation and leakiness in human intestinal organoids

Article in EMBO Molecular Medicine (February 2024)

Type-I interferon pathway and DNA damage accumulation in peripheral blood of patients with psoriatic arthritis

Article in Frontiers in Immunology (December 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.